3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
8
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
49
Nivolumab
22
Cyclophosphamide
20
fludarabine
13
Paclitaxel
9
Ipilimumab
9
atezolizumab
8
aldesleukin
8
Specimen Handling
8
Interleukin-2
7
Carboplatin
7
Magnetic Resonance Spectroscopy
6
Docetaxel
6
Biopsy
6
cemiplimab
5
fludarabine phosphate
4
durvalumab
4
Taxes
4
Gemcitabine
4
Drug Therapy
4
spartalizumab
3
poly ICLC
3
epacadostat
3
X-Rays
3
Leucovorin
3
Injections
3
Immunoglobulin G
3
Filgrastim
3
Cisplatin
3
CTLA-4 Antigen
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Colony-Stimulating Factors
×
Gynecologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled